ARFXF - ARFXF STOCK NEWS

ProMIS Neurosciences, a biotechnology firm, reported its operational and financial results for Q2 2021, with a net loss of $297,346, down from $1,650,218 in Q2 2020. The operating loss was reduced to $1,378,603, reflecting cost management and a decrease in investor relations expenses. Research and development expenses rose to $1,065,197. For the six-month period, the net loss increased to $7,896,763 compared to $3,412,137 in 2020. The company continues to focus on developing antibody therapies for neurodegenerative diseases, including its lead program PMN310 targeting Alzheimer's.

ProMIS Neurosciences recently shared updates on its participation at the 2021 Alzheimer’s Association International Conference. The report emphasizes a pivotal moment in Alzheimer's treatment following the FDA's accelerated approval of Biogen's Aduhelm, paving a clearer path for future therapies targeting neurotoxic oligomers. ProMIS's PMN310 is highlighted as a leading candidate with high selectivity for toxic oligomers and potential dual delivery methods. The company’s innovative technology platform demonstrates significant advancements in understanding neurodegeneration, particularly for Alzheimer’s and ALS.

ProMIS Neurosciences, a biotechnology firm, will present at the Alzheimer’s Association International Conference (AAIC) from July 26-30, 2021, in Denver, USA. The company’s Chief Scientific Officer, Dr. Neil Cashman, will deliver an oral presentation on targeting pathogenic TDP-43, while Chief Development Officer, Dr. Johanne Kaplan, will present a poster on toxic forms of amyloid-beta and other proteins. Both presentations will be accessible on ProMIS's website post-conference. ProMIS focuses on developing antibody therapeutics for neurodegenerative diseases like Alzheimer’s, ALS, and Parkinson’s.

ProMIS Neurosciences (OTCQB: ARFXF) has secured a final short form base shelf prospectus in Canada, facilitating offerings of securities up to US$50 million over 25 months. This prospectus enables the company to issue various securities including common shares and warrants, with specific terms to be detailed in future supplements. ProMIS focuses on developing antibody therapeutics for neurodegenerative diseases such as Alzheimer's and ALS, employing advanced predictive techniques for target discovery.

ProMIS Neurosciences, Inc. announced successful results from its annual shareholder meeting held on June 30, 2021, where all resolutions were overwhelmingly approved. A total of 104,999,925 shares were represented, accounting for 34.32% of the outstanding shares. The company re-elected its board of directors, appointed PricewaterhouseCoopers LLP as the auditor, and authorized a stock option plan. ProMIS focuses on developing antibody therapeutics for neurodegenerative diseases including Alzheimer’s, ALS, and Parkinson's.

ProMIS Neurosciences (ARFXF) applauds Biogen's FDA approval of aducanumab for Alzheimer’s, marking a pivotal moment in Alzheimer's treatment. This approval reinforces momentum in the field, with ProMIS anticipating increased interest in next-generation therapies such as its PMN310 antibody, which selectively targets toxic amyloid-beta oligomers. PMN310 uniquely avoids non-toxic forms, potentially enhancing safety and efficacy compared to other therapies. ProMIS aims to lead in developing disease-modifying treatments for Alzheimer's and other neurodegenerative diseases.

ProMIS Neurosciences (OTCQB: ARFXF) has filed a preliminary short form base shelf prospectus with Canadian securities regulators. This prospectus allows the company to offer various securities, including common shares and debt securities, for up to US$50 million over the next 25 months. While the company intends to enhance financial flexibility, it has not yet entered into any agreements to issue these securities, and may ultimately decide not to offer any. The terms of any future offerings will follow applicable securities laws.

ProMIS Neurosciences (OTCQB: ARFXF) has appointed Dr. David Wishart as Chief Physics Officer. With over three decades of experience in protein folding research, Dr. Wishart enhances ProMIS’s capability in developing therapeutics for neurodegenerative diseases, including Alzheimer's and ALS. He joins from a role on the scientific advisory board, acknowledging ProMIS's strong scientific program. The company continues to innovate within its antibody discovery platform, aiming to identify novel targets on misfolded proteins. The transition follows Dr. Steven Plotkin's tenure, ensuring continuity in leadership.

ProMIS Neurosciences has appointed Owen Dempsey to lead the commercialization of its new COVID-19 serology assay. This advanced test aims to accurately detect and quantify antibodies against SARS-CoV-2.

Utilizing cutting-edge SPR technology, the assay assesses antibody levels and their neutralizing activity against both the original strain and emerging variants of the virus. Initially, it will target medical and public health organizations, vaccine developers, and pharmaceutical companies.

This initiative is part of ProMIS’s broader focus on developing antibody therapeutics for neurodegenerative diseases.